F8 and hemophilia A: Roctavian® (valoctocogene roxaparvovec), an adeno-associated viral AAV5 vector carrying B domain-deleted FVIII complementary DNA, has been approved by the European Commission and the FDA for the treatment of severe hemophilia A in adult patients [46].